Filing summary
Filing identity mismatch: The supplied text is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2019, filed August 28, 2019. It does not appear to be a filing for Lite Strategy, Inc. or for 2017 Q4; the summary below reflects the document provided.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company. Its four clinical-stage candidates were ME-401, voruciclib, ME-344 and pracinostat. Pracinostat was in a global Phase 3 trial, while ME-401 was in a Phase 2 trial intended to support a possible FDA accelerated-approval application. The fiscal year ended June 30, 2019; comparisons are primarily with fiscal 2018.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $4.9 million | $1.6 million |
| Cost of revenue | $4.3 million | $3.4 million |
| Research and development | $32.3 million | $17.0 million |
| General and administrative | $14.6 million | $9.8 million |
| Operating loss | $46.2 million | $28.6 million |
| Reported net loss | $16.8 million | $40.1 million |
| Net cash used in operating activities | $29.4 million | $21.0 million |
Revenue was principally from license and development arrangements: $2.6 million from Kyowa Kirin (KKC) and $2.4 million from Helsinn. The company recorded a $27.6 million non-cash gain from the change in fair value of its warrant liability, substantially reducing the reported FY2019 net loss; operating performance remained loss-making. The filing also cites a $44.5 million FY2019 net loss excluding that non-cash warrant gain.
At June 30, 2019, cash and cash equivalents were $9.6 million, short-term investments $64.9 million, and common-stock proceeds receivable $5.3 million, totaling $79.8 million. Current assets were $82.2 million and current liabilities $14.3 million. Total liabilities were $34.7 million, including a $17.6 million warrant liability and deferred revenue; the filing does not report conventional borrowings. Management stated these resources were expected to fund operations into fiscal 2021 and, in the financial-statement liquidity note, for at least 12 months from issuance. No operating margin or commercial-product profitability was reported.
Material changes versus the prior comparable period
- Revenue increased to $4.9 million from $1.6 million, mainly reflecting the KKC ME-401 license and continued Helsinn-related performance obligations.
- R&D expense rose substantially, led by ME-401 Phase 2 trial and manufacturing costs; G&A also increased with staffing, share-based compensation and professional fees.
- Operating cash use increased to $29.4 million. Investing cash flow was positive $24.3 million, largely reflecting investment maturities, while financing provided $1.4 million.
- The reported net loss narrowed from $40.1 million to $16.8 million, primarily because the warrant fair-value change shifted from a $9.7 million expense in FY2018 to a $27.6 million gain in FY2019. The warrant liability declined from $46.3 million to $17.6 million.
- Revenue recognition standard ASC 606 was adopted July 1, 2018; the company reported no opening retained-earnings adjustment.
Outlook, risks and unusual items
- Management expected continued operating losses, negative operating cash flow and higher R&D spending, and anticipated needing additional capital at some point. The company had a shelf registration with $144.4 million of securities available at year-end and an ATM facility.
- ME-401 interim Phase 1b results presented in 2019 showed an 83% overall response rate among 64 evaluable patients, with approximately nine months’ median follow-up. These are interim early-stage results, not confirmatory evidence; the randomized Phase 2 study was recruiting approximately 166 patients.
- Pracinostat’s Phase 3 AML trial was Helsinn-led and funded primarily by Helsinn. ME-344 and voruciclib remained earlier-stage programs. Clinical success, regulatory approval and commercial revenue were uncertain.
- Key risks include clinical-trial failure or delay, regulatory and safety hurdles, dependence on collaborators and contract manufacturers, competition, financing needs and potential dilution, and patent or licensing challenges. Outstanding May 2018 warrants covered 16.1 million shares at $2.54 per share; 8.4 million stock options were also outstanding at year-end.
- The filing reported no legal proceedings or off-balance-sheet arrangements. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document identifies MEI Pharma and FY2019, not Lite Strategy or 2017 Q4.
- Review the subsequent clinical-trial results, timelines and safety data for ME-401 and pracinostat, and any changes to development plans for voruciclib and ME-344.
- Assess actual cash burn, financing activity and runway against management’s stated expectation, including how much cash was unrestricted and available.
- Check warrant terms, potential dilution, and the effects of warrant fair-value accounting when interpreting reported earnings.
- Verify license milestones, royalties, deferred-revenue recognition and partner performance, particularly under the KKC and Helsinn agreements.